As we kick off an exciting 2013 for biotech investors, all eyes are on Amarin's Vascepa launch. This is the company's first foray into the triglyceride-lowering space, and, as investors continue to speculate on whether it can successfully commercialize the drug, they may be forgetting about another opportunity. That, of course, is the ANCHOR indication.
In a recent presentation, Amarin's CEO suggested that the sNDA for this indication could be submitted as early as February. This expanded approval has the potential to unlock an enormous patient population -- but this isn't a guaranteed slam dunk.
In this video, health care analyst Max Macaluso discusses the potential pitfalls that Amarin could face in getting this indication approved.
What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.
The article Anchors Aweigh For This Biotech originally appeared on Fool.com.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.